ClinicalTrials.gg
TerminatedNCT03381118Updated Apr 5, 2019

Haploidentical Lymphocytes With Nivolumab/Ara-C as Consolidation in Elderly AML Patients

A Phase 2 interventional study of Cytarabine and Nivolumab in Acute Myeloid Leukemia, sponsored by St. Petersburg State Pavlov Medical University. Terminated at 1 site in Russian Federation. Open to participants aged 55 Years to 85 Years. Per ClinicalTrials.gov, last updated 2019-04-05.

Sponsored by St. Petersburg State Pavlov Medical University · Phase 2, Interventional, and Treatment

Why this study was terminated
Unexpected toxicity

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Jun 2017, registered Dec 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
55 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 247 studies testing cytarabine in Leukemia, Myeloid, Acute — 39 open to participants now, 45 under way, 10 of them phase 3. Cytarabine · Leukemia, Myeloid, Acute.

Enrollment
197th of 239
16 · median 48
Started
2017
with 5 others
Phase 2
112 of 247
21 open now
Registered
181st of 247
by date

Among the 247 studies testing cytarabine in Leukemia, Myeloid, Acute, this one is the 197th largest by enrollment of the 239 interventional ones that give a count, is one of 6 that started in 2017, is one of 112 in phase 2, and was the 181st registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 813 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

39 of the 247 studies testing cytarabine in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:

34 more — sign in →

By country, each count listing its studies:

All 39 open studies →

About cytarabine

Cytarabine: first FDA approval 1969 (CYTARABINE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 621 Leukemia, Myeloid, Acute studies recruiting now, 361 (58%) set no upper age limit and 220 (35%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 55 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 247 studies testing cytarabine in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

A phase II trial to compare the efficacy and safety of nivolumab and intermediate dose cytarabine with or without haploidentical lymphocyte infusion. To identify the role of haploidentical lymphocytes in the treatment of acute myeloid leukemia in older adults. The patients will be stratified based on the remission number (first or second)

03

Conditions studied

  • Acute Myeloid Leukemia
04

Who can participate

Ages eligible
55 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with a diagnosis of acute myeloid leukemia with the confirmed first or second complete remission
  • ≥ 55 years of age
  • Not candidates for stem cell transplantation as decided by the panel of hematologists at the transplant center
  • Patients with a HLA-haploidentical donor who should be able to provide for peripheral blood apheresis
  • No severe concurrent illness that limits to less than 2 years

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled bacterial or fungal infection at the time of enrollment
  • index \<70%
  • Acute promyelocytic leukemia
  • Other tumor requiring treatment at the time of enrollment
  • Active or prior documented disease requiring systemic treatment
  • Somatic or psychiatric disorder making the patient unable to sign
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Ara-C+HaploLymphocyte+Nivo

    Patients treated with nivolumab, intermediate dose cytarabine and haploidentical lymphocyte infusion: \[Cytarabine 500-1000 mg/m2 bid D-4, -3, -2 + G-CSF mobilized HLA-haploidentical donor peripheral blood stem cells infusion D0 + Nivolumab 40 mg D+5\] х 2-3 cycles

    Drug: Cytarabine · Drug: Nivolumab · Biological: G-CSF mobilized HLA-haploidentical donor PBSC

  • Experimental
    Ara-C+ Nivo

    Patients treated with nivolumab and intermediate dose cytarabine: \[Cytarabine 500-1000 mg/m2 bid D+1, +2, +3 + Nivolumab 40 mg D+1\] х 2-3 cycles

    Drug: Cytarabine · Drug: Nivolumab

Interventions

  • Cytarabine 500-1000 mg/m2 bid IV infusion on D-4, -3, -2

    Also known as: Ara-C

  • Nivolumab 40 mg IV infusion on D+5

    Also known as: Opdivo

  • Cytarabine 500-1000 mg/m2 bid IV infusion on D+1, +2, +3

    Also known as: Ara-C

  • Nivolumab 40 mg IV infusion on D+1

    Also known as: Opdivo

  • BiologicalG-CSF mobilized HLA-haploidentical donor PBSC

    G-CSF mobilized HLA-haploidentical donor peripheral blood stem cells IV infusion on D0

06

What researchers measure

Primary outcomes

  1. Disease-free survival

    DFS will be assessed with Kaplan-Meier method from the date of last remission before randomization until the date of relapse or the date of death

    Time frame: 2 years

Secondary outcomes

  1. Overall survival

    OS will be assessed with Kaplan-Meier method from the date of last remission before randomization until the date of death from any cause

    Time frame: 2 years

  2. Incidence of graft-versus-host disease

    Incidence of acute GVHD, grades I-IV

    Time frame: up to 12 months

  3. Treatment-related adverse events as assessed by CTCAE v4.03

    Toxicity parameters based on NCI CTCAE 4.03 grades: hematological toxicity (CBC), hepatotoxicity (liver function tests), nephrotoxicity (creatinine), neurotoxicity (attending physician assessment), fatigue (attending physician assessment), rash (attending physician assessment), colitis (attending physician assessment), pneumonitis (attending physician assessment), autoimmune disorders (level of hormones, presence of autoimmune antibodies, attending physician assessment).

    Time frame: up to 12 months

07

Study locations

1 site
  • Boris V Afanasyev, MD, Prof.
    Saint Petersburg, 197089, Russian Federation
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2017 to primary completion in Sep 2018, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2017
First posted
Dec 21, 2017
StartActual
Jun 30, 2017
Primary completionActual
Sep 30, 2018
CompletionActual
Sep 30, 2018
Last update
Apr 5, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 5, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03381118
Lead sponsor
St. Petersburg State Pavlov Medical University
Responsible party
Ivan S Moiseev (Vice-director for science of R.M. Gorbacheva Memorial Institute of Hematology, Oncology and Transplantation, St. Petersburg State Pavlov Medical University) — Principal investigator
First posted
Dec 21, 2017
Start date
Jun 30, 2017
Primary completion
Sep 30, 2018
Completion
Sep 30, 2018
Last update
Apr 5, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cytarabine

Start the discussion